Personalized Therapies in Advanced Breast Cancer
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses new personalized therapies on the horizon for advanced breast cancer.
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses new personalized therapies on the horizon for advanced breast cancer.
Clinical Pearls:
- Physicians have known for some time that there are molecular targets that are amenable to therapy
- Now that the entire genome can be sequenced, physicians are understanding more about mutations in breast cancer
- Upon sequencing the tumors of many patients with breast cancer, physicians are finding that no two tumors are the same
- New mutations may be picked up after analyzing a patient’s tumor after treatment
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
